ICON Public Limited Company (NASDAQ:ICLR) Weekly Ratings as of Dec 8, 2018

ICON Public Limited Company (NASDAQ:ICLR) Corporate Logo

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

In total 4 analysts cover Icon (NASDAQ:ICLR). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ICLR) has 100% bullish analysts. 5 are the (NASDAQ:ICLR)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Friday, October 26 the stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Outperform” rating by Evercore. On Tuesday, June 19 the firm earned “Outperform” rating by Credit Suisse. On Monday, June 18 the firm has “Overweight” rating by KeyBanc Capital Markets given. On Tuesday, September 11 the stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Outperform” rating by Robert W. Baird. On Tuesday, September 11 KeyBanc Capital Markets maintained the shares of ICLR in report with “Overweight” rating. Listed here are ICON Public Limited Company (NASDAQ:ICLR) PTs and latest ratings.

26/10/2018 Broker: Evercore Old Rating: In-Line New Rating: Outperform Upgrade
11/09/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $154 New Target: $157 Maintain
11/09/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $152 New Target: $157 Maintain
19/06/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $131 New Target: $144 Maintain
18/06/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $130 New Target: $152 Maintain

ICLR reached $139.63 during the last trading session after $2.33 change.ICON Public Limited Company has 563,435 shares volume, 108.77% up from normal. ICLR is uptrending and has moved 29.15% since December 8, 2017. ICLR outperformed by 13.53% the S&P 500.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally.The firm is worth $7.60 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.25.11 is the P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

ICON Public Limited Company (NASDAQ:ICLR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.